Tetraphase Pharmaceuticals to Present Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
April 08 2019 - 7:00AM
Business Wire
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a
biopharmaceutical company focused on developing and commercializing
novel tetracyclines to treat serious and life-threatening
conditions, today announced five data presentations at the 29th
European Congress of Clinical Microbiology and Infectious Diseases
(ECCMID), taking place April 13-16 in Amsterdam, Netherlands.
Presentations will include information about XERAVATM
(eravacycline), a tetracycline antibiotic approved for the
treatment of complicated intra-abdominal infections (cIAI), as well
as data for the Company’s clinical development candidates, TP-271
and TP-6076.
The details for the data presentations at ECCMID are as
follows:
Eravacycline poster presentations
Poster title: Multicenter evaluation of eravacycline MIC
results for Esherichia coli using MicroScan Dried Gram-negative MIC
panelsDate and time: Monday, April 15 from 12:30 – 1:30 p.m.
CEST (6:30 – 7:30 a.m. ET)Location: Paper Poster
ArenaPoster number: #P1735Session information: PS098
– Diverse methodologies for MIC testing in Gram-negatives
Poster title: In vitro activity of eravacycline and
comparators against Gram-positive bacteria collected from European
hospitals in 2017Date and time: Monday, April 15 from 1:30 –
2:30 p.m. CEST (7:30 – 8:30 a.m. ET)Location: Paper Poster
ArenaPoster number: #P1874Session information: PS107
– In vitro activity of newer antimicrobial agents
Poster title: Surveillance of the in vitro activity of
eravacycline and comparators against clinical isolates from Europe
during 2017Date and time: Monday, April 15 from 1:30 – 2:30
p.m. CEST (7:30 – 8:30 a.m. ET)Location: Paper Poster
ArenaPoster number: #P1875Session information: PS107
– In vitro activity of newer antimicrobial agents
TP-271 poster presentation
Poster title: Safety, tolerability and pharmacokinetics
of multiple doses of TP-271, a novel fluorocycline, in normal
healthy subjectsDate and time: Monday, April 15 from 1:30 –
2:30 p.m. CEST (7:30 – 8:30 a.m. ET)Location: Paper Poster
ArenaPoster number: #P2012Session information: PS116
– Safety of antibacterial agents in the clinic
TP-6076 poster presentation
Poster title: In vivo efficacy of TP-6076 in murine thigh
and lung infection models challenged with Acinetobacter
baumanniiDate and time: Monday, April 15 from 1:30 – 2:30
p.m. CEST (7:30 – 8:30 a.m. ET)Location: Paper Poster
ArenaPoster number: #P1994Session information: PS115
– Evaluation of diverse antimicrobials in vitro and experimental
models
Full abstracts can be found on the ECCMID website at
www.eccmid.org. Additional questions or follow up should be
directed to poster authors.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company
using its proprietary chemistry technology to create novel
tetracyclines for serious and life-threatening conditions,
including infections caused by many of the multidrug-resistant
bacteria highlighted as urgent public health threats by the World
Health Organization and the Centers for Disease Control and
Prevention. The Company has created more than 3,000 novel
tetracycline compounds using its proprietary technology platform.
Tetraphase's lead product XERAVATM is approved for the treatment of
complicated intra-abdominal infections by the U.S. Food and Drug
Administration and the European Medicines Agency. The Company’s
pipeline also includes TP-271 and TP-6076, which are in Phase 1
clinical trials, and TP-2846, which is in preclinical testing for
acute myeloid leukemia. Please visit www.tphase.com for more
company information.
Forward-Looking Statements
Any statements in this press release about our future
expectations, plans and prospects, including statements regarding
our strategy, future operations, prospects, plans and objectives,
including our key milestones for 2019 and our anticipated cash
runway, and other statements containing the words "anticipates,"
"believes," "expects," "plans," "will" and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including
whether our commercial launch of XERAVA in the U.S. will be
successful; our cash resources and the expected revenue will be
sufficient to fund our operations for the period anticipated; our
product candidates will succeed in clinical trials and even if the
clinical trials are successful, we may never achieve regulatory
approval of such product candidates and other clinical, regulatory
and commercial risk factors discussed in the "Risk Factors" section
of our annual report on Form 10-K for the period ended December 31,
2018, filed with the Securities and Exchange Commission on March
15, 2019. In addition, the forward-looking statements included in
this press release represent our views as of April 8, 2019.We
anticipate that subsequent events and developments will cause our
views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190408005091/en/
Jennifer Vierajviera@tphase.com617-600-7040
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Sep 2023 to Sep 2024